Taking the benefits of DAFNE to the UK and beyond

to type 1 diabetes. That caught their attention. Berger was describing was a treatment programme that improved diabetes control in real terms. In contrast to the Diabetes Control and Complications Trial (DCCT ), then still running, this was a programme that delivered lower average blood glucose concentrations and HbA1c and reduced the risk of severe hypoglycaemia. The DCCT seemed to show that this was not possible: the lower the HbA1c, the lower the risk of vascular complications but with a much higher risk of hypoglycaemia. Just over a year later, teams from King’s College Hospital London, Sheffield University and North Tyneside Hospital, all in the UK, visited Dusseldorf, Germany, to find out what Professor Berger’s team was doing.